When is ursodeoxycholic acid (UDCA) indicated in pregnancy, and what is the recommended dosage and safety profile?

Ursodeoxycholic Acid in Pregnancy

Ursodeoxycholic acid (UDCA) should be continued or initiated during pregnancy for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) at doses of 15-20 mg/kg/day, and should be offered for intrahepatic cholestasis of pregnancy (ICP) at 10-15 mg/kg/day when serum bile acids exceed 40 μmol/L, as it is safe throughout pregnancy and breastfeeding. 1, 2

Primary Indications in Pregnancy

Pre-existing Chronic Cholestatic Liver Disease

For women with PBC or PSC:

• Continue UDCA throughout pregnancy at 15-20 mg/kg/day (medium-dose range) 1
• This represents a strong recommendation with strong consensus from the 2023 EASL guidelines
• UDCA is safe during pregnancy and breastfeeding based on well-documented case series 1
• Do not discontinue when pregnancy is confirmed—this differs from obeticholic acid, which must be stopped immediately 1

Intrahepatic Cholestasis of Pregnancy (ICP)

For ICP diagnosis and treatment:

• Diagnose based on pruritus (typically second/third trimester) plus serum bile acids >10 μmol/L 2
• Initiate UDCA at 10-15 mg/kg/day in divided doses when bile acids exceed 40 μmol/L 1, 2
• Start with 10 mg/kg/day and slowly increase to 20 mg/kg/day if needed 1
• UDCA reduces risk of spontaneous preterm birth and may protect against stillbirth 1

Important nuance regarding ICP treatment efficacy: The 2019 PITCHES trial 3 showed that UDCA did not reduce the composite outcome of perinatal death, preterm delivery, or NICU admission in ICP. However, the 2023 EASL guidelines 1 still recommend UDCA based on meta-analyses showing reduction in preterm birth and stillbirth. The guidelines prioritize the potential mortality benefit despite modest effects on maternal symptoms. The effect on pruritus may fall below the minimum clinically worthwhile threshold, but even mild improvement can be psychologically beneficial for women with severe symptoms 1.

Dosing Algorithms

For Chronic Cholestatic Disease (PBC/PSC)

• Standard dose: 15-20 mg/kg/day 1
• Continue same dose used pre-pregnancy
• No dose adjustment needed during pregnancy

For ICP

• Initial dose: 10 mg/kg/day divided twice daily 1, 2
• Titration: Gradually increase to 15-20 mg/kg/day as tolerated 1
• Practical dosing: Typically 500 mg twice daily, adjustable from 250 mg daily to 1000 mg twice daily based on response 2

Emerging evidence on gradual dosing: A 2024 study 4 suggests that gradually increasing UDCA dose (rather than starting with full dose) may improve composite neonatal outcomes and allow greater gestational age at delivery. While this requires prospective validation, consider starting lower and titrating up in ICP cases.

Safety Profile

Maternal Safety

• Well-tolerated with excellent safety profile 1
• Medium-dose UDCA is regarded as safe during pregnancy 1
• Most common side effect: dose-dependent diarrhea 5
• No association with liver damage or enzyme abnormalities 6

Fetal Safety

• No evidence of fetal harm in animal studies at 20-100 fold human doses 6
• Inadvertent first-trimester exposure in 4 women showed no adverse fetal effects 6
• Safe throughout all trimesters and during breastfeeding 1

Critical FDA labeling caveat: The FDA label 6 states UDCA "is not recommended for use during pregnancy" because adequate controlled studies are lacking. However, this conflicts with current clinical guidelines which strongly recommend its use based on extensive real-world safety data. Prioritize the 2023 EASL guidelines over the outdated FDA labeling when counseling patients.

Management of Pruritus

For cholestasis-associated pruritus not adequately controlled by UDCA:

• Rifampicin: 300-600 mg daily 1
• Anion exchange resins: Cholestyramine 4-8 g/day or colestipol 5-10 g/day 1
• Critical timing: Give bile acid sequestrants at least 4 hours after UDCA to avoid reducing UDCA absorption 1
• Non-pharmacologic: emollients, avoid hot baths, cooling menthol gels, keep nails short 1

Important Drug Interactions

Avoid concurrent administration with:

• Cholestyramine or colestipol (separate by ≥4 hours) 1, 6
• Aluminum-based antacids (reduce UDCA absorption) 6

Medications that may counteract UDCA efficacy:

• Estrogens and oral contraceptives (increase cholesterol secretion) 6
• Clofibrate and other lipid-lowering drugs 6

Monitoring Requirements

For PBC/PSC During Pregnancy

• Monitor liver enzymes (AST/ALT) at initiation and as clinically indicated 1
• Correct vitamin K deficiency related to cholestasis or bile acid sequestrant use 1
• Ultrasound or MRCP if cholestasis worsens to exclude biliary obstruction 1

For ICP During Pregnancy

• Check serum bile acids at least weekly as they may continue rising with advancing gestation 1
• Monitor liver enzymes (ALT/AST typically 10-20× upper limit of normal) 2
• Bilirubin rarely elevated; if markedly raised, investigate other causes 1

Delivery Timing Based on Bile Acid Levels

For ICP, delivery timing depends on bile acid severity:

• Bile acids >100 μmol/L: Deliver at 36 weeks or at diagnosis if after 36 weeks (stillbirth risk increases markedly after 35 weeks) 1, 2
• Bile acids <100 μmol/L: Deliver at 36-39 weeks depending on when diagnosed 2
• Bile acids <40 μmol/L: Consider delivery at term 2

Common Pitfalls to Avoid

1. Do not discontinue UDCA when pregnancy is confirmed in women with PBC/PSC—this differs from obeticholic acid management 1

2. Do not give bile acid sequestrants simultaneously with UDCA—separate by at least 4 hours to prevent binding and reduced absorption 1

3. Do not rely solely on symptom improvement in ICP—UDCA has modest effects on pruritus but the primary goal is reducing adverse perinatal outcomes 1, 3

4. Do not assume gallbladder nonvisualization is a contraindication—it's acceptable before starting therapy, but if it develops during treatment, discontinue UDCA as it predicts treatment failure 6

5. Do not forget vitamin K supplementation—cholestasis and bile acid sequestrant use increase deficiency risk 1

Breastfeeding

UDCA is safe during breastfeeding and should be continued in women with PBC or PSC 1. While it's unknown whether UDCA is excreted in human milk 6, clinical guidelines support its use based on extensive safety data.